Contact Information: Contacts: Vipin Adhlakha BioServe 301-470-3362 Email Contact Constantine Theodoropulos Boston Communications 617-619-9801 Email Contact
BioServe Unveils New DNA Methylation Service
| Source: BioServe
LAUREL, MD -- (MARKET WIRE) -- December 11, 2006 -- BioServe Biotechnologies, a leader for fast,
economical processing and analyses of genomic content from biological
samples, today introduced its new DNA Methylation Analysis Service using
Sequenom, Inc.'s (NASDAQ : SQNM ) MassARRAY® System and EpiTYPER™
methodology. DNA methylation markers are a new and important class of
biomarkers that are significant because of their correlation to gene
activity. High levels of cytosine methylation in genomic regions (CpG
islands) are often associated with decreased or completely inhibited gene
expression. Researchers now believe that DNA methylation patterns play an
important role in early cancer detection and prognosis. BioServe's
Methylation Analysis Service will aid researchers' understanding of
methylation patterns with quantitative results in the form of methylation
ratios in targeted genomic regions.
"DNA methylation patterns affect phenotype and cell biology, as most
obviously seen in cancers. Understanding this epigenetic dysregulation is
essential to potentially mediating many common diseases. BioServe's new
Methylation Analysis Service will help researchers studying a variety of
diseases, identify CpG disturbances in the genome and gain new insights
into the roots of disease," said Rama Modali, President of BioServe. "For
example, our Methylation Service gives researchers the ability to
efficiently measure methylation activity at individual sites in the genome
and quantitatively measure methylation ratios across multiple methylation
sites over multiple samples."
About BioServe
BioServe delivers a complete 'biomaterial to validated data' genomics
solution. BioServe's fast, economical processing and analyses of genomic
content from biological samples helps researchers worldwide to gain the
pre-clinical genomic results required to achieve breakthroughs in research,
drug discovery and molecular diagnostics. BioServe's technology, products
and services form the foundation for optimal pre-clinical workflows
spanning innovative methodologies for processing nucleic acids, DNA
synthesis, high throughput sequencing and genotyping, genome wide-scans and
gene expression analyses. BioServe's customers include leading
pharmaceutical and biotechnology companies, and government and academic
research institutions. BioServe has headquarters in Laurel, MD and
Hyderabad, India. For more information please visit www.bioserve.com or
call 301-470-3362.
Sequenom®, MassARRAY®, EpiTYPER™, and iPLEX™ are trademarks of
Sequenom, Inc.